SNGX OTC/bb. PR. Staging. 1/4/12 FDA to Initiat
Post# of 63699
Posted On: 01/06/2013 10:31:31 AM
SNGX OTC/bb. PR. Staging.
1/4/12 FDA to Initiate Program Evaluating OrbeShieldTM as a Therapy for Gastrointestinal Acute radiation syndrome (GI-ARS).
Soligenix has previously received Orphan Drug Designation for oral BDP for the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
(0)
(0)Scroll down for more posts ▼